FDA grants priority review of acalabrutinib for second-line treatment of MCLAugust 2, 2017Mantle Cell Lymphoma
IMiD/Anti-CD20 combo induces complete responses in r/r NHLJuly 19, 2017Mantle Cell LymphomaAggressive Lymphomas
Bendamustine plus rituximab may have edge for treating indolent NHL, MCLJune 22, 2017Mantle Cell LymphomaIndolent Lymphoma
In mantle cell lymphoma, triple therapy proves too toxicApril 24, 2017Mantle Cell LymphomaAggressive Lymphomas
Newly diagnosed mantle cell lymphoma is ‘one of the hardest consultations’April 21, 2017Mantle Cell Lymphoma
Unavoidable, random DNA replication errors are the most common cancer driversMarch 23, 2017PediatricsPatient & Survivor CareHodgkin LymphomaMantle Cell Lymphoma
Phase III trial: VZV protects auto-HCT patientsFebruary 25, 2017Multiple MyelomaT Cell LymphomasMantle Cell LymphomaIndolent LymphomaAggressive Lymphomas
